Ramesh K et al [25] conducted another phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. This evidence concerns the gene MUC1 and pancreatic neoplasm.